Journal of Medicinal Chemistry · 2004 · 31 citations · 16 references
MedicineMedicinal ChemistryPharmacologyBiochemical PharmacologyMolecular PharmacologySignal TransductionIon Channel PharmacologyIon Channel PhysiologyIon Channel RegulationIon Channel SignalingIon ChannelsPancreatic HormonesPancreatic Islet CellsPharmacological PotencyPotassium Channel FunctionPotassium Channel GatingPotassium Channel OpenersPotassium Channel PharmacologyPotassium Channel RegulationVascular Smooth Muscle Pharmacology
Five series (ureas, thioureas, carbamates, sulfonylureas, and amides) of 4,6-disubstituted-2,2-dimethylchromans structurally related to cromakalim were prepared and evaluated, as putative ATP-sensitive potassium channel activators, on rat pancreatic islets and rat aorta rings. The biological data indicate that most compounds were, like the reference molecule cromakalim, more active on the vascular smooth muscle tissue (myorelaxant effect on 30 mM KCl induced contractions of rat aorta rings) than on the pancreatic tissue (inhibition of 16.7 mM glucose induced insulin release from rat pancreatic islets). However, some drugs (8h, 8i, 9f, 9g, 9h, and 9i) markedly inhibited insulin release and exhibited an activity equivalent or greater than that of diazoxide. Compounds 9h and 9i were also found to be more active on pancreatic beta-cells than on vascular smooth muscle cells. Last, the amide 6b was selected in order to examine its mechanism of action on vascular smooth muscle cells. Pharmacological results suggest that the compound acted as a K(ATP) channel opener. In conclusion, the present data indicate that appropriate structural modifications can generate dimethylchromans with pharmacological profiles different from that of cromakalim.
16
ATP-regulated K+ channels in cardiac muscle
Akinori Noma · Nature · 1983 · 2.3K citations
The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity
Raymond W. Sweet, Shiro Yokoyama, Tohru Kamata et al. · Nature · 1984 · 540 citations